Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...

These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...

Faster eschar removal: NexoBrid achieved complete eschar removal ... MediWound is advancing EscharEx ®, a promising candidate currently in Phase III development for the debridement of chronic wounds.

Faster eschar removal: NexoBrid achieved complete ... a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... in Phase III development for the debridement of chronic wounds.

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns ... and non-surgical alternative for eschar removal in pediatric burn patients ...

Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration ... was easily removed with debridement scissors (see Figure ...